The 40 patient single-blinded clinical trial was conducted in the EU. It was designed to demonstrate DM-99’s effectiveness at changing blood glucose levels in patients diagnosed with type 2 diabetes, after they consumed a standardized meal.
Change in insulin or blood glucose levels was the study’s primary endpoint. Each patient was tested for both the effects of treatment with DM-99 and a placebo, and therefore served as their own control in this cross over study.
Reginald Bowerman, president and CEO of DiaMedica, said: “We believe that DM-99 may both insulin sensitize and hasten the onset of insulin action. We look forward to the outcome of this Phase II trial in light of the compelling pre-clinical research results.”